Investor Alert: Robbins LLP Informs Investors of the Novo Nordisk A/S Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S, alleging that the company misled investors regarding its revenue and profit growth potential for 2025 [2][4]. Group 1: Allegations - The lawsuit claims that Novo Nordisk overstated its growth potential, failing to account for the impact of the personalization exception to the compounded GLP-1 exclusion [2]. - It is alleged that the company misrepresented the likelihood of patients transitioning from compounded GLP-1s to its branded alternatives [2]. - The complaint also states that Novo Nordisk significantly overstated the size of the GLP-1 market and its ability to penetrate that market for sustained growth [2]. Group 2: Financial Outlook - On July 29, 2025, Novo Nordisk announced a reduction in its sales and profit outlook, attributing this to lower growth expectations for its products Wegovy and Ozempic due to persistent use of compounded GLP-1s and increased competition [3]. - Following this announcement, Novo Nordisk's stock price fell from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025 [3]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must submit their papers by September 30, 2025, to serve as lead plaintiff [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4].